US Launches Trade Probe into German Drug Pricing Practices

The United States Trade Representative (USTR) has initiated an investigation into Germany's drug reimbursement policies. This Section 301 probe will examine whether Germany's low reimbursement rates for innovative medicines are harming U.S. trade. The USTR aims to determine if these practices violate trade agreements and negatively impact American pharmaceutical companies. The investigation will assess the economic impact of Germany's pricing strategies on the U.S. market. This move signals a potential escalation in trade disputes between the two economic powers. The outcome could lead to retaliatory measures if violations are found. German officials are expected to respond to the U.S. concerns.

This investigation highlights ongoing tensions over pharmaceutical pricing and market access, with potential implications for global trade relations and healthcare costs.